Author

Tracey Rawls

Institution: Celldex Therapeutics (United States)

Observed institution: Celldex Therapeutics (United States)

OpenAlex ID: A5072567296

Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors

2022 · Rachel E Sanborn, Michael J Pishvaian, et al. · Journal for ImmunoTherapy of Cancer · 68

Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, for hematologic malignancies

2020 · Stephen M. Ansell, Ian Flinn, et al. · Blood Advances · 68

Clinical results with combination of anti-CD27 agonist antibody, varlilumab, with anti-PD1 antibody nivolumab in advanced cancer patients.

2017 · Rachel E. Sanborn, Michael J. Pishvaian, et al. · Journal of Clinical Oncology · 22

Anti-CD27 agonist antibody varlilumab (varli) with nivolumab (nivo) for colorectal (CRC) and ovarian (OVA) cancer: Phase (Ph) 1/2 clinical trial results.

2018 · Rachel E. Sanborn, Michael J. Pishvaian, et al. · Journal of Clinical Oncology · 18

ATIM-23. ANTI-CD27 AGONIST ANTIBODY VARLILUMAB IN COMBINATION WITH NIVOLUMAB FOR RECURRENT GLIOBLASTOMA (rGBM): PHASE 2 CLINICAL TRIAL RESULTS

2018 · David Reardon, Thomas Kaley, et al. · Neuro-Oncology · 11

405 CDX1140–01, a phase 1 dose-escalation/expansion study of CDX-1140 alone (Part 1) and in combination with CDX-301 (Part 2) or pembrolizumab (Part 3)

2020 · Rachel Sanborn, Ralph Hauke, et al. · Regular and Young Investigator Award Abstracts · 10

Abstract LB-194: First-in-human Phase I study of the CD40 agonist mAb CDX-1140 and in combination with CDX-301 (rhFLT3L) in patients with advanced cancers: Interim results

2019 · Rachel E. Sanborn, Nashat Y. Gabrail, et al. · Cancer Research · 10

Abstract CT023: Phase I results from the combination of an immune-activating anti-CD27 antibody (varlilumab) in combination with PD-1 blockade (nivolumab): activation across multiple immune pathways without untoward immune-related adverse events

2016 · Rachel E. Sanborn, Michael J. Pishvain, et al. · Cancer Research · 10

A phase 1 dose-escalation study of a PD-L1xCD27 bispecific antibody CDX-527 in patients with advanced malignancies.

2021 · Rachel E. Sanborn, Rodolfo Eduardo Bordoni, et al. · Journal of Clinical Oncology · 6

Preliminary results from a first-in-human phase 1 study of the CD40 agonist monoclonal antibody (mAb) CDX-1140

2018 · Rachel E. Sanborn, Michael S. Gordon, et al. · 1

Immune correlates of varlilumab (CDX-1127) treated cancer patients are consistent with CD27 costimulatory activity

2014 · Timothy N. J. Bullock, Hillary McClintic, et al. · F1000Research · 1

406 CDX527–01, a phase 1 dose-escalation and expansion study of the PD-L1xCD27 bispecific antibody CDX-527 in patients with advanced malignancies

2020 · Michael Yellin, Tracey Rawls, et al. · Regular and Young Investigator Award Abstracts

Abstract LB-194: First-in-human Phase I study of the CD40 agonist mAb CDX-1140 and in combination with CDX-301 (rhFLT3L) in patients with advanced cancers: Interim results

2019 · Rachel E. Sanborn, Nashat Y. Gabrail, et al. · Immunology

Works count: 13

Citation count: 225

H-index: 8

I10-index: 8